Figure 5.

Swimmer's plot of 31 patients who had evaluable brain metastases showing duration of best brain response and duration of osimertinib use after central nervous system progression. Patients with lines that terminate with arrows were still alive and receiving osimertinib at last follow‐up. Patients with lines that terminate without arrows were known to be no longer receiving osimertinib because of death, progression of disease, toxicity, or unknown reason, as stated.

Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.